Translational Research

Approaches to cancer treatment are increasingly being shaped by advances in genomic science and the development of molecular targeted therapies. Identifying patients with key biomarkers will help patients and their providers to make treatment choices that maximize positive outcomes and minimize risk for negative side effects. ECRI scientists work closely with clinicians in the JCC Disease Site Teams to identify target populations who may benefit most from advances in the laboratory, and with health services researchers to help shape the health care system and health policy to ensure these advances become part of practice.